Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Stockholm - Delayed Quote SEK

Stayble Therapeutics AB (publ) (STABL.ST)

Compare
0.4480
-0.0520
(-10.40%)
At close: April 4 at 5:12:09 PM GMT+2
Loading Chart for STABL.ST
  • Previous Close 0.5000
  • Open 0.5390
  • Bid 0.4030 x --
  • Ask 0.4280 x --
  • Day's Range 0.4005 - 0.5390
  • 52 Week Range 0.1900 - 1.0500
  • Volume 661,531
  • Avg. Volume 429,647
  • Market Cap (intraday) 19.587M
  • Beta (5Y Monthly) 0.14
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3300
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Stayble Therapeutics AB (publ) develops injectable treatment for chronic pain triggered by disc degeneration. The company develops STA363, an injection into the disc that targets chronic low back and leg pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.

www.staybletherapeutics.se

2

Full Time Employees

December 31

Fiscal Year Ends

Recent News: STABL.ST

View More

Performance Overview: STABL.ST

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

STABL.ST
12.16%
OMX Stockholm 30 Index (^OMX)
7.89%

1-Year Return

STABL.ST
59.15%
OMX Stockholm 30 Index (^OMX)
9.30%

3-Year Return

STABL.ST
92.06%
OMX Stockholm 30 Index (^OMX)
7.06%

5-Year Return

STABL.ST
93.86%
OMX Stockholm 30 Index (^OMX)
62.84%

Compare To: STABL.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: STABL.ST

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    19.59M

  • Enterprise Value

    17.39M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.85

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -53.22%

  • Return on Equity (ttm)

    -106.23%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -12.42M

  • Diluted EPS (ttm)

    -0.3300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.19M

  • Total Debt/Equity (mrq)

    12.37%

  • Levered Free Cash Flow (ttm)

    -10.52M

Research Analysis: STABL.ST

View More

Company Insights: STABL.ST

Research Reports: STABL.ST

View More

People Also Watch